Hashem B El-Serag

List of Publications by Citations

Source: https://exaly.com/author-pdf/461725/hashem-b-el-serag-publications-by-citations.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

435 papers	51,669 citations	101 h-index	222 g-index
478 ext. papers	60,285 ext. citations	6.3 avg, IF	8.64 L-index

#	Paper	IF	Citations
435	Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*, **2007**, 132, 2557-76	13.3	4148
434	Hepatocellular carcinoma. *New England Journal of Medicine*, **2011**, 365, 1118-27	59.2	3015
433	Rising incidence of hepatocellular carcinoma in the United States. *New England Journal of Medicine*, **1999**, 340, 745-50	59.2	2692
432	Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology*, **2012**, 142, 1264-1273.e1	13.3	2241
431	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell*, **2017**, 169, 1327-1341.e23	56.2	1125
430	Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut*, **2014**, 63, 871-80	19.2	1035
429	Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology*, **2004**, 126, 460-8	13.3	922
428	The epidemiology of cholangiocarcinoma. *Seminars in Liver Disease*, **2004**, 24, 115-25	7.3	912
427	Diagnosis and treatment of hepatocellular carcinoma. *Gastroenterology*, **2008**, 134, 1752-63	13.3	842
426	Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology*, **2004**, 127, S27-34	13.3	805
425	Epidemiology of hepatocellular carcinoma: consider the population. *Journal of Clinical Gastroenterology*, **2013**, 47 Suppl, S2-6	3	803
424	Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Annals of Internal Medicine*, **2005**, 143, 199-211	8	801
423	Esophageal carcinoma. *New England Journal of Medicine*, **2014**, 371, 2499-509	59.2	790
422	The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. *Annals of Internal Medicine*, **2003**, 139, 817-23	8	734
421	Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. *Gastroenterology*, **2010**, 138, 513-21, 521.e1-6	13.3	720
420	The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clinical Gastroenterology and Hepatology*, **2006**, 4, 369-80	6.9	620
419	Epidemiology and Management of Hepatocellular Carcinoma. *Gastroenterology*, **2019**, 156, 477-491.e1	13.3	595

418	Risk factors for cholangiocarcinoma. *Hepatology*, **2011**, 54, 173-84	11.2	572
417	Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. *Journal of Hepatology*, **2004**, 40, 472-7	13.4	559
416	Hepatocellular carcinoma: an epidemiologic view. *Journal of Clinical Gastroenterology*, **2002**, 35, S72-8	3	515
415	Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 1342-1359.e2	6.9	486
414	Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. *Gastroenterology*, **2017**, 153, 996-1005.e1	13.3	461
413	Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. *Hepatology*, **2014**, 60, 1767-75	11.2	439
412	Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. *Gastroenterology*, **2005**, 128, 620-6	13.3	431
411	Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. *Gastroenterology*, **2004**, 127, 1372-80	13.3	418
410	Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. *American Journal of Gastroenterology*, **2005**, 100, 1243-50	0.7	416
409	Obesity: a challenge to esophagogastric junction integrity. *Gastroenterology*, **2006**, 130, 639-49	13.3	414
408	The changing pattern of epidemiology in hepatocellular carcinoma. *Digestive and Liver Disease*, **2010**, 42 Suppl 3, S206-14	3.3	409
407	The epidemiology of obesity. *Gastroenterology Clinics of North America*, **2010**, 39, 1-7	4.4	391
406	Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 1221-8	6.9	387
405	Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. *Hepatology*, **2011**, 54, 463-71	11.2	372
404	Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 2140-51	6.9	337
403	Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 124-31.e1	6.9	334
402	Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. *Gastrointestinal Endoscopy*, **2008**, 67, 394-8	5.2	326
401	Time trends of gastroesophageal reflux disease: a systematic review. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 17-26	6.9	317

400	Risk factors for the rising rates of primary liver cancer in the United States. *Archives of Internal Medicine*, **2000**, 160, 3227-30		309
399	Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. *Journal of Hepatology*, **2008**, 49, 831-44	13.4	301
398	Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. *American Journal of Gastroenterology*, **2004**, 99, 1877-83	0.7	301
397	Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. *Gastroenterology*, **2011**, 140, 1182-1188.e1	13.3	296
396	Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. *Hepatology*, **2001**, 33, 62-5	11.2	293
395	Burden of Gastric Cancer. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 534-542	6.9	290
394	Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. *Hepatology*, **2010**, 52, 132-41	11.2	277
393	Epidemiology of Hepatocellular Carcinoma. *Hepatology*, **2021**, 73 Suppl 1, 4-13	11.2	272
392	Epidemiology of hepatocellular carcinoma. *Clinics in Liver Disease*, **2001**, 5, 87-107, vi	4.6	264
391	Hepatocellular carcinoma and hepatitis C in the United States. *Hepatology*, **2002**, 36, S74-S83	11.2	263
390	Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. *Gastroenterology*, **2017**, 152, 812-820.e5	13.3	262
389	Epidemiology of hepatocellular carcinoma in USA. *Hepatology Research*, **2007**, 37 Suppl 2, S88-94	5.1	262
388	Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. *Hepatology*, **2016**, 64, 130-7	11.2	254
387	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. *Gastroenterology*, **2018**, 155, 1828-1837.e2	13.3	248
386	Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. *JAMA - Journal of the American Medical Association*, **2007**, 297, 2010-7	27.4	244
385	Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. *Cancer Control*, **2017**, 24, 1073274817729245	2.2	235
384	Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. *Annals of Internal Medicine*, **2011**, 154, 85-93	8	234
383	Global epidemiology and burden of HCV infection and HCV-related disease. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 122-132	24.2	233

382	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 223-238	24.2	228
381	Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 1399-1412.e7	6.9	224
380	AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. *Gastroenterology*, **2020**, 159, 320-334.e27	13.3	223
379	The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. *American Journal of Gastroenterology*, **2001**, 96, 2462-7	0.7	221
378	Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. *American Journal of Gastroenterology*, **2013**, 108, 1314-21	0.7	217
377	Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. *American Journal of Gastroenterology*, **2007**, 102, 1016-21	0.7	216
376	Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. *Hepatology*, **2004**, 39, 798-803	11.2	215
375	Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. *Gastroenterology*, **2009**, 136, 1601-8	13.3	207
374	Gastroesophageal reflux among different racial groups in the United States. *Gastroenterology*, **2004** , 126, 1692-9	13.3	205
373	Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. *Hepatology*, **2009**, 49, 116-23	11.2	203
372	Obesity increases oesophageal acid exposure. *Gut*, **2007**, 56, 749-55	19.2	199
371	Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. *Gastroenterology*, **2015**, 149, 340-9.e2	13.3	198
370	Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. *Journal of Hepatology*, **2006**, 44, 158-66	13.4	198
369	Psychiatric disorders among veterans with hepatitis C infection. *Gastroenterology*, **2002**, 123, 476-82	13.3	198
368	HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. *Hepatology*, **2014**, 60, 98-105	11.2	197
367	AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. *Gastroenterology*, **2020**, 159, 739-758.e4	13.3	192
366	Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. *Gut*, **2014**, 63, 1229-37	19.2	190
365	Hepatocellular carcinoma and hepatitis C in the United States. *Hepatology*, **2002**, 36, S74-83	11.2	188

364	Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. *American Journal of Gastroenterology*, **2003**, 98, 1627-33	0.7	174
363	Abdominal obesity and the risk of Barrett's esophagus. *American Journal of Gastroenterology*, **2005**, 100, 2151-6	0.7	173
362	Lifestyle Intervention in Gastroesophageal Reflux Disease. *Clinical Gastroenterology and Hepatology* , **2016**, 14, 175-82.e1-3	6.9	172
361	A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1198-1203	4	172
360	Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. *BMC Medical Research Methodology*, **2018**, 18, 1	4.7	170
359	Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 594-601.e1	6.9	166
358	Symptomatic reflux disease: the present, the past and the future. *Gut*, **2014**, 63, 1185-93	19.2	162
357	Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. *Gastroenterology*, **2001**, 121, 1294-9	13.3	156
356	Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. *American Journal of Gastroenterology*, **2001**, 96, 979-83	0.7	155
355	Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. *Gastroenterology*, **2010**, 138, 2260-6	13.3	150
354	Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. *American Journal of Gastroenterology*, **2000**, 95, 3566-73	0.7	150
353	Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. *Journal of Hepatology*, **2019**, 71, 104-114	13.4	144
352	Extrahepatic manifestations of hepatitis C among United States male veterans. *Hepatology*, **2002**, 36, 1439-45	11.2	139
351	The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. *American Journal of Gastroenterology*, **2005**, 100, 56-63	0.7	138
350	Extrahepatic manifestations of hepatitis C among United States male veterans. *Hepatology*, **2002**, 36, 1439-1445	11.2	138
349	Medication usage and the risk of neoplasia in patients with Barrett's esophagus. *Clinical Gastroenterology and Hepatology*, **2009**, 7, 1299-304	6.9	133
348	A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. *Gastroenterology*, **2014**, 146, 1249-55.e1	13.3	129
347	Is there a true "shift" to the right colon in the incidence of colorectal cancer?. *American Journal of Gastroenterology*, **2003**, 98, 1400-9	0.7	123

346	Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. *Archives of Internal Medicine*, **2004**, 164, 2349-54		122
345	Gastric Cancer as Preventable Disease. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1833-1843	6.9	119
344	Anthropometric correlates of intragastric pressure. *Scandinavian Journal of Gastroenterology*, **2006**, 41, 887-91	2.4	119
343	Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. *Journal of Pediatrics*, **2007**, 150, 262-7, 267.e1	3.6	116
342	Diabetes increases the risk of acute hepatic failure. *Gastroenterology*, **2002**, 122, 1822-8	13.3	116
341	Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 301-8.e1-2	6.9	113
340	Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. *Journal of Clinical Gastroenterology*, **2002**, 35, 266-9	3	112
339	Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. *Journal of Clinical Oncology*, **2008**, 26, 474-9	2.2	111
338	Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 992-1002.e6	6.9	107
337	Epidemiology of hepatocellular carcinoma in Hispanics in the United States. *Archives of Internal Medicine*, **2007**, 167, 1983-9		107
336	Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1616-24	6.9	101
335	The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. *Gastroenterology*, **2012**, 143, 70-7	13.3	101
334	Role of obesity in GORD-related disorders. *Gut*, **2008**, 57, 281-4	19.2	101
333	Gastroesophageal reflux and asthma in children: a systematic review. *Pediatrics*, **2010**, 125, e925-30	7.4	100
332	Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. *American Journal of Epidemiology*, **2008**, 167, 377-89	3.8	99
331	Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. *Hepatology*, **2020**, 71, 44-55	11.2	99
330	AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. *Gastroenterology*, **2020**, 158, 1822-1830	13.3	94
329	Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. *Gut*, **2014**, 63, 220-9	19.2	94

328	Utilization of screening for hepatocellular carcinoma in the United States. *Journal of Clinical Gastroenterology*, **2007**, 41, 777-82	3	92
327	Surveillance for hepatocellular carcinoma: in whom and how?. *Therapeutic Advances in Gastroenterology*, **2011**, 4, 5-10	4.7	89
326	The epidemic of esophageal adenocarcinoma. *Gastroenterology Clinics of North America*, **2002**, 31, 421-40, viii	4.4	89
325	Missed opportunities to initiate endoscopic evaluation for colorectal cancer diagnosis. *American Journal of Gastroenterology*, **2009**, 104, 2543-54	0.7	86
324	Oral contraception and the risk of hepatocellular carcinoma. *Journal of Hepatology*, **2007**, 47, 506-13	13.4	86
323	Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. *Gut*, **2016**, 65, 1252-60	19.2	85
322	AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. *Gastroenterology*, **2020**, 158, 693-702	13.3	84
321	Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. *Journal of Hepatology*, **2016**, 65, 1148-1154	13.4	83
320	Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 191-202.e1-4; quiz e20	6.9	80
319	Nonalcoholic fatty liver disease is underrecognized in the primary care setting. *American Journal of Gastroenterology*, **2015**, 110, 10-4	0.7	79
318	Gaps in the achievement of effectiveness of HCV treatment in national VA practice. *Journal of Hepatology*, **2012**, 56, 320-5	13.4	79
317	Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 373-381.e1	6.9	76
316	Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. *Hepatology*, **2011**, 53, 737-45	11.2	75
315	Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 273-281.e1	6.9	74
314	Age at onset of GERD symptoms predicts risk of Barrett's esophagus. *American Journal of Gastroenterology*, **2013**, 108, 915-22	0.7	74
313	Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. *Gut*, **2011**, 60, 992-7	19.2	73
312	Childhood GERD is a risk factor for GERD in adolescents and young adults. *American Journal of Gastroenterology*, **2004**, 99, 806-12	0.7	73
311	Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1220-1228.e4	6.9	72

310	The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis. *Helicobacter*, **2012**, 17, 163-75	4.9	72
309	The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. *Archives of Internal Medicine*, **2006**, 166, 2202-8		72
308	Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. *Liver Transplantation*, **2005**, 11, 1370-8	4.5	72
307	Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. *Gastroenterology*, **2015**, 149, 119-29	13.3	71
306	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. *Journal of Hepatology*, **2018**, 69, 278-285	13.4	70
305	Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. *American Journal of Gastroenterology*, **2014**, 109, 1427-35	0.7	69
304	Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. *Digestive Diseases and Sciences*, **2014**, 59, 3103-10	4	69
303	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. *Journal of Hepatology*, **2019**, 70, 639-647	13.4	69
302	The Epidemiology of Hepatocellular Carcinoma in the USA. *Current Gastroenterology Reports*, **2019**, 21, 17	5	67
301	Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. *Journal of Pediatric Gastroenterology and Nutrition*, **2008**, 47, 141-6	2.8	67
300	Survival of colorectal cancer patients hospitalized in the Veterans Affairs Health Care System. *American Journal of Gastroenterology*, **2003**, 98, 1186-92	0.7	67
299	Surgical volume and long-term survival following surgery for colorectal cancer in the Veterans Affairs Health-Care System. *American Journal of Gastroenterology*, **2004**, 99, 668-75	0.7	67
298	Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. *American Journal of Gastroenterology*, **2005**, 100, 1002-8	0.7	67
297	Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. *Journal of Hepatology*, **2017**, 66, 355-362	13.4	66
296	Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. *American Journal of Gastroenterology*, **2011**, 106, 483-91	0.7	66
295	Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. *Journal of Clinical Gastroenterology*, **2012**, 46, 71-7	3	66
294	Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. *Journal of Hepatology*, **2005**, 42, 309-14	13.4	66
293	Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. *American Journal of Gastroenterology*, **2008**, 103, 120-7	0.7	64

292	Association Between Laparoscopic Antireflux Surgery and Recurrence of Gastroesophageal Reflux. *JAMA - Journal of the American Medical Association*, **2017**, 318, 939-946	27.4	62
291	Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 229-238.e3	6.9	62
290	Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. *Gastroenterology*, **2015**, 149, 1599-606	13.3	61
289	Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. *American Journal of Gastroenterology*, **2006**, 101, 2485-92	0.7	60
288	The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study. *Gastrointestinal Endoscopy*, **2006**, 64, 671-5	5.2	60
287	Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. *Hepatology*, **2013**, 58, 538-45	11.2	59
286	Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 508-12	6.9	59
285	Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. *Journal of Clinical Gastroenterology*, **2004**, 38, 530-4	3	59
284	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. *Hepatology*, **2020**, 71, 808-819	11.2	59
283	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 61-71.e13	6.9	58
282	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. *Cancer Research*, **2019**, 79, 4326-4330	10.1	57
281	Endoscopic manifestations of gastroesophageal reflux disease in patients between 18 months and 25 years without neurological deficits. *American Journal of Gastroenterology*, **2002**, 97, 1635-9	0.7	57
280	A multibiomarker risk score helps predict risk for Barrett's esophagus. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 1267-71	6.9	56
279	Association between Helicobacter pylori and Barrett's esophagus: a case-control study. *American Journal of Gastroenterology*, **2014**, 109, 357-68	0.7	55
278	Underdiagnosis of Lynch syndrome involves more than family history criteria. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 523-9	6.9	55
277	Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. *Hepatology*, **2012**, 55, 759-68	11.2	54
276	Epidemiology of non-erosive reflux disease. *Digestion*, **2008**, 78 Suppl 1, 6-10	3.6	54
275	The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?. *American Journal of Gastroenterology*, **2003**, 98, 2535-42	0.7	54

274	Esophageal carcinoma. *New England Journal of Medicine*, **2015**, 372, 1472-3	59.2	53
273	Prevalence of Barrett's Esophagus in Asian Countries: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1907-18	6.9	53
272	Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. *Hepatology*, **2016**, 64, 569-81	11.2	53
271	Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. *Digestive Diseases and Sciences*, **2016**, 61, 1714-20	4	52
270	A research agenda for curing chronic hepatitis B virus infection. *Hepatology*, **2018**, 67, 1127-1131	11.2	51
269	Helicobacter pylori-negative gastritis: prevalence and risk factors. *American Journal of Gastroenterology*, **2013**, 108, 65-71	0.7	51
268	Dietary quality and the colonic mucosa-associated gut microbiome in humans. *American Journal of Clinical Nutrition*, **2019**, 110, 701-712	7	50
267	Menopausal hormone therapy and the risk of esophageal and gastric cancer. *International Journal of Cancer*, **2017**, 140, 1693-1699	7.5	49
266	Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. *Molecular Carcinogenesis*, **2013**, 52 Suppl 1, E139-47	5	49
265	Characteristics of intestinal metaplasia in the gastric cardia. *American Journal of Gastroenterology*, **1999**, 94, 622-7	0.7	48
264	Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. *Hepatology*, **2011**, 53, 1060-1; author reply 1061-2	11.2	46
263	Outcomes of surgical fundoplication in children. *Clinical Gastroenterology and Hepatology*, **2004**, 2, 978-84	6.9	45
262	Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. *Journal of Clinical Gastroenterology*, **2005**, 39, 731-6	3	45
261	Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1207-1217.e4	6.9	44
260	Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). *American Journal of Gastroenterology*, **2003**, 98, 471-7	0.7	44
259	Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. *Clinical Infectious Diseases*, **2016**, 63, 291-9	11.6	44
258	Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 428-33	6.9	43
257	Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. *Hepatology*, **2014**, 60, 1871-8	11.2	42

256	Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. *Hepatology*, **2011**, 53, 42-52	11.2	41
255	Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. *Journal of Viral Hepatitis*, **2019**, 26, 596-602	3.4	40
254	Level of Fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 989-94	6.9	39
253	The Prevalence of Helicobacter pylori Remains High in African American and Hispanic Veterans. *Helicobacter*, **2015**, 20, 305-15	4.9	38
252	The incidence and prevalence of inflammatory bowel disease among U.S. veterans: a national cohort study. *Inflammatory Bowel Diseases*, **2013**, 19, 1059-64	4.5	38
251	Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study. *Journal of Clinical Gastroenterology*, **2007**, 41, 911-7	3	38
250	Postoperative 30-day mortality following surgical resection for colorectal cancer in veterans: changes in the right direction. *Digestive Diseases and Sciences*, **2005**, 50, 1722-8	4	38
249	Burden of Pancreatic Cancer: From Epidemiology to Practice. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 876-884	6.9	38
248	Gastric Microbiota in -Negative and -Positive Gastritis Among High Incidence of Gastric Cancer Area. *Cancers*, **2019**, 11,	6.6	37
247	Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. *Gastroenterology*, **2015**, 149, 1392-8	13.3	37
246	No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. *Digestive Diseases and Sciences*, **2014**, 59, 108-16	4	37
245	Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. *Hepatology*, **2013**, 57, 1858-68	11.2	37
244	Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. *International Journal of Epidemiology*, **2018**, 47, 966-975	7.8	36
243	Celiac sprue among US military veterans: associated disorders and clinical manifestations. *Digestive Diseases and Sciences*, **1999**, 44, 966-72	4	36
242	Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. *American Journal of Gastroenterology*, **2017**, 112, 1287-1297	0.7	35
241	The impact of HIV viral control on the incidence of HIV-associated anal cancer. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2013**, 63, 631-8	3.1	35
240	Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. *Journal of Hepatology*, **2020**, 73, 1425-1433	13.4	34
239	Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. *American Journal of Gastroenterology* , **2018**, 113, 1148-1155	0.7	34

238	Determinants of gastroesophageal reflux disease in adults with a history of childhood gastroesophageal reflux disease. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 696-701	6.9	34
237	Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States. *Annals of Surgical Oncology*, **2007**, 14, 2519-27	3.1	34
236	Clinical Manifestations of Helicobacter pylori-Negative Gastritis. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1037-1046.e3	6.9	33
235	Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1677-1678	6.9	33
234	Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1531-1532	6.9	33
233	Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing. *Medical Care*, **2016**, 54, e9-14	3.1	33
232	Obesity and disease of the esophagus and colon. *Gastroenterology Clinics of North America*, **2005**, 34, 63-82	4.4	33
231	Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. *Journal of Viral Hepatitis*, **2016**, 23, 687-96	3.4	33
230	Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1521-31.e3	6.9	32
229	The quality of care provided to patients with varices in the department of Veterans Affairs. *American Journal of Gastroenterology*, **2014**, 109, 934-40	0.7	32
228	Statin therapy and serum transaminases among a cohort of HCV-infected veterans. *Digestive Diseases and Sciences*, **2010**, 55, 190-5	4	32
227	Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 252-259	6.9	31
226	Gene expression in Barrett's esophagus: laser capture versus whole tissue. *Scandinavian Journal of Gastroenterology*, **2009**, 44, 787-95	2.4	31
225	The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 1442-1447	6.1	30
224	Statin use is associated with a decreased risk of Barrett's esophagus. *Gastroenterology*, **2014**, 147, 314-23	13.3	30
223	Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. *American Journal of Gastroenterology*, **2014**, 109, 1870-80	0.7	29
222	Geographic variation within the United States in the incidence of hepatocellular carcinoma. *Journal of Clinical Epidemiology*, **2003**, 56, 487-93	5.7	29
221	The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. *Gastroenterology*, **2015**, 149, 1986-7	13.3	28

220	Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. *Journal of the National Cancer Institute*, **2018**, 110,	9.7	27
219	Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. *Digestive Diseases and Sciences*, **2010**, 55, 3404-7	4	27
218	Barrett's esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what's next?. *American Journal of Gastroenterology*, **2014**, 109, 178-82	0.7	26
217	Automated identification of surveillance colonoscopy in inflammatory bowel disease using natural language processing. *Digestive Diseases and Sciences*, **2013**, 58, 936-41	4	26
216	Gastric mucosal microbiota in a Mongolian population with gastric cancer and precursor conditions. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 770-780	6.1	25
215	Reducing referral delays in colorectal cancer diagnosis: is it about how you ask?. *BMJ Quality and Safety*, **2010**, 19, e27	5.4	25
214	Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System. *Digestive Diseases and Sciences*, **2010**, 55, 1434-41	4	25
213	Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. *Reviews in Gastroenterological Disorders*, **2003**, 3 Suppl 2, S3-11		25
212	Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. *American Journal of Gastroenterology*, **2016**, 111, 1528-1535	0.7	24
211	Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBPÞ300 Axis. *Cell Reports*, **2018**, 24, 1597-1609	10.6	24
210	Incidence and survival of colorectal cancer among Hispanics in the United States: a population-based study. *Digestive Diseases and Sciences*, **2013**, 58, 2052-60	4	24
209	Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. *American Journal of Gastroenterology*, **2006**, 101, 1727-33	0.7	24
208	Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. *Surgery for Obesity and Related Diseases*, **2017**, 13, 28-34	3	23
207	Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. *Nutrients*, **2019**, 11,	6.7	23
206	Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome. *Digestive Diseases and Sciences*, **2014**, 59, 2913-26	4	23
205	The use of cytokeratin stain to distinguish Barrett's esophagus from contiguous tissues: a systematic review. *Digestive Diseases and Sciences*, **2007**, 52, 1345-54	4	23
204	Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. *Clinical Gastroenterology and Hepatology*, **2005**, 3, 175-83	6.9	23
203	Outcome of erosive reflux esophagitis after Nissen fundoplication. *American Journal of Gastroenterology*, **1999**, 94, 1771-6	0.7	23

202	Ethnic variations in the occurrence of gastroesophageal cancers. *Journal of Clinical Gastroenterology*, **1999**, 28, 135-9	3	23
201	Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. *Journal of Viral Hepatitis*, **2018**, 25, 543-551	3.4	23
200	Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 20-36	6.1	22
199	Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. *Hepatology*, **2020**, 72, 1242-1252	11.2	22
198	The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus. *American Journal of Gastroenterology*, **2014**, 109, 1862-8; quiz 1861, 1869	0.7	22
197	Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. *Journal of Clinical Gastroenterology*, **2014**, 48, 218-23	3	21
196	Patient-Reported Attributions for Missed Colonoscopy Appointments in Two Large Healthcare Systems. *Digestive Diseases and Sciences*, **2016**, 61, 1853-61	4	20
195	Practice patterns of surveillance endoscopy in a Veterans Affairs database of 29,504 patients with Barrett's esophagus. *Gastrointestinal Endoscopy*, **2012**, 76, 743-55	5.2	20
194	The big burden of obesity. *Gastrointestinal Endoscopy*, **2009**, 70, 752-7	5.2	20
193	Cholangiocarcinoma: the "other" liver cancer on the rise. *American Journal of Gastroenterology*, **2002**, 97, 3199-200	0.7	20
192	Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. *American Journal of Gastroenterology*, **2020**, 115, 381-387	0.7	20
191	Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1886-1893.e5	6.9	19
190	Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 1832-9.e6	6.9	19
189	Barrett's esophagus in children and adolescents without neurodevelopmental or tracheoesophageal abnormalities: a prospective study. *Gastrointestinal Endoscopy*, **2011**, 73, 875-80	5.2	19
188	Epidemiology of Hepatocellular Carcinoma **2020**, 758-772		19
187	Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis. *Inflammatory Bowel Diseases*, **2012**, 18, 1011-7	4.5	18
186	Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 65-72.e5	6.9	18
185	Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. *JAMA Network Open*, **2020**, 3, e2023780	10.4	18

184	External Validation of the Michigan Barrett's Esophagus Prediction Tool. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1124-1126	6.9	17
183	Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. *Digestive Diseases and Sciences*, **2017**, 62, 526-533	4	17
182	Opportunities for Preventing Esophageal Adenocarcinoma. *Cancer Prevention Research*, **2016**, 9, 828-834	3.2	17
181	Cholangiocarcinoma: the "other" liver cancer on the rise. *American Journal of Gastroenterology*, **2002**, 97, 3199-3200	0.7	17
180	Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2117-2125.e3	6.9	17
179	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*, **2021**, 161, 1657-1669	13.3	17
178	Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. *Digestive Diseases and Sciences*, **2018**, 63, 3112-3119	4	16
177	The performance of process measures in hepatitis C. *American Journal of Gastroenterology*, **2012**, 107, 1512-21	0.7	16
176	Is there a true "shift" to the right colon in the incidence of colorectal cancer?. *American Journal of Gastroenterology*, **2003**, 98, 1400-1409	0.7	16
175	Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 657-665.e13	6.9	16
174	The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. *American Journal of Gastroenterology*, **2018**, 113, 1310	0.7	16
173	Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. *European Journal of Cancer*, **2017**, 75, 41-46	7.5	15
172	A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women. *Cancer Prevention Research*, **2019**, 12, 237-246	3.2	15
171	Limited life expectancy among a subgroup of medicare beneficiaries receiving screening colonoscopies. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 443-450.e1	6.9	15
170	Human papillomavirus and the risk of Barrett's esophagus. *Ecological Management and Restoration*, **2013**, 26, 517-21	3	15
169	Surveillance for hepatocellular carcinoma: development and validation of an algorithm to classify tests in administrative and laboratory data. *Digestive Diseases and Sciences*, **2010**, 55, 3241-51	4	15
168	Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. *Journal of Surgical Research*, **2016**, 200, 552-9	2.5	15
167	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. *American Journal of Gastroenterology*, **2019**, 114, 530-532	0.7	15

166	Management of the single liver nodule in a cirrhotic patient: a decision analysis model. *Journal of Clinical Gastroenterology*, **2005**, 39, 152-9	3	15
165	Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. *Digestive Diseases and Sciences*, **2018**, 63, 1551-1557	4	14
164	Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. *Digestive Diseases and Sciences*, **2017**, 62, 2713-2718	4	14
163	Process of care for hepatitis C infection is linked to treatment outcome and virologic response. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 1270-1277.e3	6.9	14
162	Inflammatory bowel disease characteristics and treatment in Hispanics and Caucasians. *Digestive Diseases and Sciences*, **2011**, 56, 1476-81	4	14
161	Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. *Clinical Gastroenterology and Hepatology*, **2004**, 2, 296-300	6.9	14
160	Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. *Digestive Diseases and Sciences*, **2013**, 58, 3117-26	4	13
159	Use and yield of endoscopy in patients with uncomplicated gastroesophageal reflux disorder. *JAMA Internal Medicine*, **2014**, 174, 462-5	11.5	13
158	Prevalence and determinants of histological abnormalities of the gastric cardia in volunteers. *Scandinavian Journal of Gastroenterology*, **2007**, 42, 1158-66	2.4	13
157	Assessment of disease specific knowledge and health-related quality of life among United States military veterans with inflammatory bowel disease. *World Journal of Gastroenterology*, **2015**, 21, 6001-7	5.6	13
156	Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. *Digestive Diseases and Sciences*, **2019**, 64, 367-372	4	13
155	Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 88-94	4	12
154	WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients. *PLoS ONE*, **2013**, 8, e84407	3.7	12
153	Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. *Gastroenterology*, **2020**, 159, 376-377	13.3	12
152	The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. *American Journal of Gastroenterology*, **2017**, 112, 1049-1055	0.7	11
151	Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women's Health Initiative Study. *Journal of Clinical Medicine*, **2018**, 7,	5.1	11
150	A Systematic Review of the Effectiveness of Psychological Treatments for IBS in Gastroenterology Settings: Promising but in Need of Further Study. *Digestive Diseases and Sciences*, **2018**, 63, 2189-2201	4	11
149	Patient experiences with surveillance endoscopy: a qualitative study. *Digestive Diseases and Sciences*, **2014**, 59, 1378-85	4	11

148	Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. *Digestive Diseases and Sciences*, **2020**, 65, 2403-2411	4	11
147	A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women. *Cancer Epidemiology*, **2016**, 42, 115-23	2.8	11
146	European Registry on management shows that gastroenterology has largely failed in its efforts to guide practitioners. *Gut*, **2021**, 70, 1-2	19.2	11
145	Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking. *Digestive Diseases and Sciences*, **2015**, 60, 65-73	4	10
144	Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1616-1621.e1	6.9	10
143	Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. *Digestive Diseases and Sciences*, **2018**, 63, 1173-1181	4	10
142	How we approach it: treatment options for hepatocellular carcinoma. *American Journal of Gastroenterology*, **2018**, 113, 791-794	0.7	10
141	Republished: symptomatic reflux disease: the present, the past and the future. *Postgraduate Medical Journal*, **2015**, 91, 46-54	2	10
140	Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. *American Journal of Gastroenterology*, **2013**, 108, 1576-83	0.7	10
139	Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males. *International Journal of Molecular Epidemiology and Genetics*, **2014**, 5, 164-76	0.9	10
138	Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease. *Journal of Family Practice*, **2010**, 59, S37-42	0.2	10
137	Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1443-1450.e6	6.9	10
136	Medical comorbidity and distress in patients with irritable bowel syndrome: The moderating role of age. *Journal of Psychosomatic Research*, **2016**, 88, 48-53	4.1	10
135	Prevalence of Barrett's esophagus and performance of societal screening guidelines in an unreferred primary care population of U.S. veterans. *Gastrointestinal Endoscopy*, **2021**, 93, 409-419.e1	5.2	10
134	Polymorphisms of 5-HTT LPR and GNB3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. *American Journal of Gastroenterology*, **2017**, 112, 903-909	0.7	9
133	Reply to: "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma". *Journal of Hepatology*, **2019**, 71, 1262-1263	13.4	9
132	Coffee or Tea, Hot or Cold, Are Not Associated With Risk of Barrett's Esophagus. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 769-72	6.9	9
131	Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 310-312	6.9	9

130	Hepatocellular cancer care: cost is important but only one factor of disease burden. *Journal of Hepatology*, **2009**, 50, 10-2	13.4	9
129	Is genomic evaluation feasible in endoscopic studies of Barrett's esophagus? A pilot study. *Gastrointestinal Endoscopy*, **2006**, 64, 17-26	5.2	9
128	Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma. *International Journal of Molecular Epidemiology and Genetics*, **2012**, 3, 294-304	0.9	9
127	Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. *Hepatology*, **2021**,	11.2	9
126	GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis. *Hepatology*, **2021**,	11.2	9
125	The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2020**, 26, 1423-1428	4.5	9
124	Determinants of Healthcare Utilization Among Veterans with Inflammatory Bowel Disease. *Digestive Diseases and Sciences*, **2017**, 62, 607-614	4	8
123	A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. *Cancer Medicine*, **2018**, 7, 2180-2191	4.8	8
122	Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1412-1419.e3	6.9	8
121	Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 327-333.e1	6.9	8
120	Mortality associated with gastroesophageal reflux disease and its non-malignant complications: a systematic review. *Scandinavian Journal of Gastroenterology*, **2008**, 43, 645-53	2.4	8
119	Gastric microbiota and Helicobacter pylori in Indonesian population. *Helicobacter*, **2020**, 25, e12695	4.9	7
118	Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. *Journal of Gastroenterology and Hepatology (Australia)*, **2020**, 35, 1684-1693	4	7
117	Helicobacter pylori Infection. *New England Journal of Medicine*, **2019**, 381, 587-588	59.2	7
116	CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 200-3	6.9	7
115	Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1965-1967	6.9	7
114	Preparing for the NASH Epidemic: A Call to Action. *Gastroenterology*, **2021**, 161, 1030-1042.e8	13.3	7
113	Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV. *Digestive Diseases and Sciences*, **2017**, 62, 76-83	4	6

112	Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. *Digestive Diseases and Sciences*, **2019**, 64, 3328-3336	4	6
111	Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 280-6	6.9	6
110	Barrett's esophagus: best practices for treatment and post-treatment surveillance. *Annals of Cardiothoracic Surgery*, **2017**, 6, 75-87	4.7	6
109	Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. *Cancer*, **2019**, 125, 4210-4223	6.4	6
108	Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study. *Annals of Hepatology*, **2017**, 16, 16-20	3.1	6
107	Epidemiology of Gastroesophageal Reflux Disease. *Progress in Surgery*, **1997**, 23, 20-36		6
106	Artificial intelligence in gastroenterology: A state-of-the-art review. *World Journal of Gastroenterology*, **2021**, 27, 6794-6824	5.6	6
105	Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. *Antiviral Research*, **2020**, 174, 104698	10.8	6
104	Alcohol use alters the colonic mucosa-associated gut microbiota in humans. *Nutrition Research*, **2020**, 83, 119-128	4	6
103	Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1679-1687	6.9	6
102	Gastro-oesophageal reflux disease. *Nature Reviews Disease Primers*, **2021**, 7, 55	51.1	6
101	Recommendations for Successful Transition of Adolescents With Inflammatory Bowel Diseases to Adult Care. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 276-289.e2	6.9	6
100	Prevalence of Gastric Intestinal Metaplasia in a Multiethnic US Veterans Population. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 269-276.e3	6.9	6
99	Rational HCC screening approaches for patients with NAFLD. *Journal of Hepatology*, **2021**,	13.4	6
98	Sleep Duration and Risk of Liver Cancer in Postmenopausal Women: The Women's Health Initiative Study. *Journal of Womens Health*, **2017**, 26, 1270-1277	3	5
97	Epidemiology of Hepatocellular Carcinoma **2016**, 3-24		5
96	Bundling in medicare patients undergoing bidirectional endoscopy: how often does it happen?. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 58-63	6.9	5
95	Improving quality of care in patients with cirrhosis. *Clinical Liver Disease*, **2013**, 2, 123-124	2.2	5

94	CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. *Gastroenterology*, **2013**, 144, 478-81	13.3	5
93	Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy. *BMC Health Services Research*, **2012**, 12, 288	2.9	5
92	The dawn of a new era: transforming our domestic response to hepatitis B & C. *Gastroenterology*, **2010**, 138, 1225-30, 1230.e1-3	13.3	5
91	Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. *International Journal of Molecular Epidemiology and Genetics*, **2017**, 8, 8-18	0.9	5
90	Preparing for the NASH Epidemic: A Call to Action. *Diabetes Care*, **2021**, 44, 2162-2172	14.6	5
89	Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. *Digestive Diseases and Sciences*, **2021**, 66, 912-916	4	5
88	Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. *Cancer Causes and Control*, **2021**, 32, 317-325	2.8	5
87	Applying Lean Design Principles to a Gastrointestinal Endoscopy Program for Uninsured Patients Improves Health Care Utilization. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1556-9.e4	6.9	4
86	Spotlight: COVID-19 PPE and Endoscopy. *Gastroenterology*, **2020**, 159, 759	13.3	4
85	Scientific manuscripts: the fun of writing and submitting. *Gastrointestinal Endoscopy*, **2006**, 64, S19-22	5.2	4
84	Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis. *Helicobacter*, **2021**, 26, e12790	4.9	4
83	Preparing for the NASH epidemic: A call to action. *Metabolism: Clinical and Experimental*, **2021**, 122, 154822	22.7	4
82	Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. *Journal of Hepatology*, **2021**,	13.4	4
81	Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1. *Gastroenterology Research and Practice*, **2019**, 2019, 5290642	2	3
80	Curbside Consultations: The Good, the Bad, and the Ugly. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 2-4	6.9	3
79	Is Proton Pump Inhibitor Use Associated With Risk of Myocardial Infarction?. *Gastroenterology*, **2016**, 150, 526-7	13.3	3
78	Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. *Digestive Diseases and Sciences*, **2014**, 59, 273-81	4	3
77	Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. *Digestive Diseases and Sciences*, **2015**, 60, 2030-7	4	3

76	Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients. *Journal of Clinical Gastroenterology*, **2013**, 47, 545-52	3	3
75	Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. *Digestive Diseases and Sciences*, **2011**, 56, 1835-47	4	3
74	Manuscript writing. *Gastrointestinal Endoscopy*, **2008**, 67, 311-2	5.2	3
73	The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC). A Phase 3 Biomarker Study in the United States.. *Clinical Gastroenterology and Hepatology*, **2022**,	6.9	3
72	Associations of Duration, Intensity, and Quantity of Smoking With Risk of Gastric Intestinal Metaplasia. *Journal of Clinical Gastroenterology*, **2022**, 56, e71-e76	3	3
71	Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. *Digestive Diseases and Sciences*, **2020**, 65, 2691-2699	4	3
70	External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. *Digestive Diseases and Sciences*, **2021**, 66, 2387-2393	4	3
69	Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. *Digestive Diseases and Sciences*, **2021**, 66, 2439-2451	4	3
68	Habitual Sleep Duration and the Colonic Mucosa-Associated Gut Microbiota in Humans-A Pilot Study. *Clocks & Sleep*, **2021**, 3, 387-397	2.9	3
67	Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases. *PLoS ONE*, **2016**, 11, e0169250	3.7	3
66	Increasing Incidence of Advanced Non-cardia Gastric Cancers Among Younger Hispanics in the USA. *Digestive Diseases and Sciences*, **2021**, 66, 1669-1672	4	3
65	Current Status of Chemoprevention in Barrett's Esophagus. *Gastrointestinal Endoscopy Clinics of North America*, **2021**, 31, 117-130	3.3	3
64	The treatment path in hepatocellular carcinoma. *Clinical Advances in Hematology and Oncology*, **2017**, 15 Suppl 9, 1-20	0.6	3
63	Race/Ethnicity and Birthplace as Risk Factors for Gastric Intestinal Metaplasia in a Multiethnic United States Population.. *American Journal of Gastroenterology*, **2021**, 117,	0.7	3
62	Clinical and psychosocial variables associated with behavioral intentions to undergo surveillance endoscopy. *BMC Gastroenterology*, **2014**, 14, 107	3	2
61	How to Prepare for and Write a Grant: Personal Perspectives. *Gastroenterology*, **2017**, 152, 7-11	13.3	2
60	Finasteride and methadone use and risk of advanced hepatitis C related liver disease. *Digestive Diseases and Sciences*, **2012**, 57, 3004-10	4	2
59	Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease. *Journal of Clinical Gastroenterology*, **2012**, 46, 779-88	3	2

58	The epidemic of esophageal adenocarcinoma. *Hematology/Oncology Clinics of North America*, **2003**, 17, 413-432	3.1	2
57	Guideline adherence for diagnosis of liver cancer in veterans.. *Journal of Clinical Oncology*, **2013**, 31, 89-89	2.2	2
56	Oral Health and the Altered Colonic Mucosa-Associated Gut Microbiota. *Digestive Diseases and Sciences*, **2021**, 66, 2981-2991	4	2
55	Obesity and Gastroesophageal Reflux Disease **2021**, 624-632		2
54	Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or Associated With Nonadherence) Identify Possible Health Care System Quality Measures. *Gastroenterology*, **2019**, 156, 809-811	13.3	2
53	Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans. *Digestive Diseases and Sciences*, **2021**, 66, 1600-1610	4	2
52	A multidisciplinary approach to improving transition readiness in pediatric liver transplant recipients. *Pediatric Transplantation*, **2021**, 25, e13839	1.8	2
51	Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. *Microbial Ecology*, **2021**, 1	4.4	2
50	Risk for Post-Colonoscopy Irritable Bowel Syndrome in Patients With and Without Antibiotic Exposure: A Retrospective Cohort Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	2
49	Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. *Digestive Diseases and Sciences*, **2019**, 64, 1470-1477	4	1
48	Durability and Effectiveness of Cognitive-Behavioral Therapy for Irritable Bowel Syndrome. *Gastroenterology*, **2019**, 157, 1684-1686	13.3	1
47	Epidemiology of esophageal carcinoma **2015**, 1-14		1
46	Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma: How Common?. *Current Hepatology Reports*, **2015**, 14, 87-98	1	1
45	Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis **2012**, 142-156		1
44	Surveillance for hepatocellular carcinoma: does it work?. *American Journal of Gastroenterology*, **2002**, 97, 2676-7	0.7	1
43	Interferon for postresection recurrence of hepatocellular carcinoma. *American Journal of Gastroenterology*, **2002**, 97, 3200-2	0.7	1
42	Letter: are microbes other than Helicobacter pylori associated with gastric cancer? Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 1447-1449	6.1	1
41	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. *Hepatology*, **2021**,	11.2	1

40	Alcohol consumption and the risk of gastric intestinal metaplasia in a U.S. Veterans population. *PLoS ONE*, **2021**, 16, e0260019	3.7	1
39	Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas. *Open Forum Infectious Diseases*, **2020**, 7, ofaa191	1	1
38	The Influence of Gut and Tumor Microbiome on Pancreatic Cancer Outcomes. *Gastroenterology*, **2020**, 159, 1184-1185	13.3	1
37	Functional Dyspepsia and Duodenal Eosinophil Count and Degranulation: A Multiethnic US Veteran Cohort Study. *Digestive Diseases and Sciences*, **2021**, 66, 3482-3489	4	1
36	A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. *Cancer Prevention Research*, **2021**, 14, 667-674	3.2	1
35	Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	1
34	Reply. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 2005-2006	6.9	1
33	Chemoprevention of Barrett's oesophagus: a step closer with PPIs and aspirin. *Nature Reviews Clinical Oncology*, **2018**, 15, 728-730	19.4	1
32	Preparing for the NASH epidemic: A call to action. *Obesity*, **2021**, 29, 1401-1412	8	1
31	Advances in the management of hepatocellular carcinoma. *Clinical Advances in Hematology and Oncology*, **2017**, 15 Suppl 9, 2-6	0.6	1
30	Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease.. *Clinical Gastroenterology and Hepatology*, **2022**,	6.9	1
29	The Art and Science of Managing Liver Disease. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 2029-30	6.9	0
28	Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population. *Digestive Diseases and Sciences*, **2021**, 1	4	0
27	Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System. *Open Forum Infectious Diseases*, **2020**, 7, ofaa322	1	0
26	Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease.. *Scientific Reports*, **2022**, 12, 5695	4.9	0
25	Anniversary Tribute From the Editors of Clinical Gastroenterology and Hepatology. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1823-1827	6.9	
24	Prospective implementation of algorithmic patient selection for gastrostomy tube placement consultations: a pre- and post-intervention analysis. *Clinical and Experimental Gastroenterology*, **2019**, 12, 231-237	3.1	
23	Premature Birth and Large for Gestational Age Are Associated with Risk of Barrett's Esophagus in Adults. *Digestive Diseases and Sciences*, **2016**, 61, 1139-47	4	

22	Prevalence of Celiac Disease Among Unsuspected Patients Presenting to Open Access Endoscopy. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 137-139	6.9
21	Response to Braillon. *American Journal of Gastroenterology*, **2013**, 108, 1931	0.7
20	Epidemiology of Hepatocellular Carcinoma **2009**, 1-25	
19	The risk of hepatocellular carcinoma in patients with previous malignancy. *Cancer Investigation*, **2008**, 26, 511-5	2.1
18	Epidemiology of Hepatocellular Carcinoma409-420	
17	Prevalence and histological features of the gastric cardia-type mucosa in children. *Digestive Diseases and Sciences*, **2008**, 53, 1792-6	4
16	Emerging epidemiologic observations in HCV/HIV coinfection. *Current Hepatitis Reports*, **2006**, 5, 162-171	
15	Gastroesophageal Reflux and the Obesity Epidemic. *Gastroenterology and Hepatology*, **2006**, 2, 795-796	0.7
14	Risk Factors for Hepatocellular Carcinoma: A Historical Perspective. *Clinical Liver Disease*, **2021**, 18, 1-13	2.2
13	Reply. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9
12	Epidemiology of Hepatocellular Carcinoma **2010**, 51-73	
11	Are Patterns and Prevalence Changing?1-10	
10	Utilization and outcomes of primary tumor surgery for stage IV colon cancer in the United States: A population-based study.. *Journal of Clinical Oncology*, **2012**, 30, 3542-3542	2.2
9	The effect of gaps in chemotherapy in patients with stage IV colorectal cancer.. *Journal of Clinical Oncology*, **2013**, 31, e17501-e17501	2.2
8	How to Find and Apply Large Databases for Epidemiologic Research83-97	
7	Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with Barrett esophagus: A systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2014**, 32, 11-11	2.2
6	Our New President-John M. Inadomi, MD, AGAF. *Gastroenterology*, **2021**, 160, 2149-2154	13.3
5	Weight Change and Weight Cycling Are Not Associated With Risk of Barrett's Esophagus. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1839-1840	6.9

4	Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1912-1914	6.9
3	Reply. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 2004	6.9
2	Endoscopic Ultrasound Finding of Diffuse Echogenicity in the Pancreas, Is It Relevant?. *Digestive Diseases and Sciences*, **2021**, 1	4
1	Why Do Small Intraductal Papillary Mucinous Neoplasms Create Such a Huge Management Challenge?: How International Classification of Diseases Codes Have Failed Us.. *Pancreas*, **2022**, 51, e13-e15	2.6